List of Excipients in Branded Drug VIDAZA

Vidaza Excipient Strategy and Commercial Opportunities for Azacitidine

Last updated: September 3, 2026

Vidaza is the injectable formulation of azacitidine, a hypomethylating agent used primarily in myelodysplastic syndromes and acute myeloid leukemia treatment protocols. Its formulation is commercially simple: a 100 mg lyophilized vial containing azacitidine and mannitol, reconstituted with sterile water for injection. The primary opportunity is not a complex excipient patent estate. It is the development of lower-waste presentations, more convenient reconstitution systems, improved in-use stability, and differentiated hospital products that reduce pharmacy labor and product loss.

Vidaza's core composition is readily reproducible, and historical U.S. patents have expired. Generic competition therefore depends more on FDA approval, manufacturing reliability, vial economics, supply continuity, and handling advantages than on composition-of-matter exclusivity.

What is Vidaza and how is azacitidine formulated?

Vidaza contains azacitidine, a cytidine nucleoside analogue that inhibits DNA methyltransferase after incorporation into DNA and RNA. The U.S. product is supplied as a sterile lyophilized powder in a 100 mg single-dose vial.

Attribute	Vidaza
Active ingredient	Azacitidine
Dosage form	Lyophilized powder for injection
Strength	100 mg per vial
Routes	Subcutaneous or intravenous
Principal excipient	Mannitol
Reconstitution	Sterile water for injection
U.S. sponsor	Celgene, now part of Bristol Myers Squibb
Original U.S. approval	2004
Main therapeutic area	Myelodysplastic syndromes
Typical dosing schedule	75 mg/m² daily for seven days in repeated treatment cycles
Regulatory category	Small-molecule drug, not biologic

The U.S. label requires different handling depending on the route. Subcutaneous administration uses a reconstituted suspension. Intravenous administration requires further dilution in an infusion solution. The label also imposes storage and administration limits after reconstitution, creating a practical formulation opportunity around stability and workflow simplification.[1]

What excipients are used in Vidaza?

The key excipient in the U.S. Vidaza vial is mannitol. Mannitol provides bulking capacity during lyophilization and supports formation of a physically acceptable cake. It also has a long regulatory history in injectable products.

The formulation is commercially attractive because it avoids a complex excipient system. It does not depend on a proprietary lipid carrier, polymer matrix, surfactant package, or device-linked delivery technology. The main formulation risks are azacitidine degradation, reconstitution performance, suspension uniformity, sterility, and product handling.

Vidaza excipient profile

Formulation component	Function	Commercial assessment
Azacitidine	Active pharmaceutical ingredient	Sensitive to hydrolysis and degradation in aqueous conditions
Mannitol	Lyophilization bulking agent and cake former	Widely available and difficult to protect through broad composition claims
Sterile water	Reconstitution diluent	Usually supplied separately or sourced by the institution
Sodium chloride infusion solution	IV dilution vehicle	Used for intravenous administration under the product label
Container closure system	Maintains sterility and product integrity	Potential source of manufacturing and quality differentiation

The simplicity of the excipient system limits the value of a conventional "me-too" excipient patent. A new formulation must show a material advantage, such as longer in-use stability, reduced degradation, lower reconstitution time, reduced aggregation, or improved dose recovery.

What formulation patents could protect improved azacitidine products?

The strongest formulation opportunities concern product configuration and performance rather than mannitol itself.

Ready-to-use liquid azacitidine

A ready-to-use liquid product could eliminate vial reconstitution and reduce pharmacy preparation time. The technical barrier is azacitidine's aqueous stability. A viable product would need a stabilizing pH environment, appropriate concentration, low particulate generation, and a commercially useful shelf life.

Potential claim categories include:

• Azacitidine liquid compositions with defined pH ranges.
• Stabilized solutions with specified degradation limits.
• Container systems that limit oxygen or moisture exposure.
• Premixed IV bags or syringe presentations.
• Ready-to-administer subcutaneous formulations.
• Liquid products with defined storage periods after opening or preparation.

A liquid formulation would face greater regulatory scrutiny than a simple lyophilized generic because the sponsor would need to establish stability, container compatibility, preservative strategy, and potentially a clinical bridge.

Improved lyophilized formulations

An improved lyophilized product could retain mannitol while optimizing the cycle and reconstitution profile. Claims could cover:

• Mannitol concentration ranges.
• Additional buffers or pH modifiers.
• Stabilizers that limit azacitidine degradation.
• Cake structure and residual moisture.
• Reconstitution time.
• Suspension particle-size distribution.
• Dose recovery after transfer to an administration syringe.
• Defined in-use stability under refrigerated or room-temperature conditions.

The patent value would depend on measurable performance. A patent directed only to substituting one common bulking agent for another would face substantial obviousness risk.

Smaller and multi-strength vials

Vidaza dosing is based on body-surface area, while the U.S. product is supplied in 100 mg vials. A 75 mg/m² regimen can generate unused product, depending on patient size and institutional dose-banding practice.

Commercially relevant presentations include:

• 50 mg vials.
• 25 mg vials.
• 100 mg vials with improved residual-volume performance.
• Dual-vial kits containing matched diluent.
• Pharmacy-ready dose-banded presentations.
• Closed-system transfer-compatible packaging.

A smaller vial could reduce drug wastage but increase filling, labeling, packaging, and inventory costs. The opportunity is strongest in high-volume oncology centers that perform repeated azacitidine cycles.

How can excipient strategy reduce azacitidine drug waste?

Waste reduction is likely the clearest commercial value proposition.

The standard seven-day regimen creates repeated preparation events. Institutional waste depends on the patient's calculated dose, vial size, batching policy, beyond-use dating, and whether multiple patients can receive doses from the same preparation session.

A product developer can target waste through:

1. Smaller vial sizes that better match common dose ranges.
2. Longer validated in-use stability that allows same-day batching.
3. Ready-to-use presentations that reduce overfill and transfer loss.
4. Improved vial and syringe dose recovery.
5. Pharmacy-compatible packaging that reduces partial-vial discard.
6. Dose-banded presentations for common body-surface-area categories.

The commercial analysis should measure total treatment-cycle cost, not only acquisition price. A product with a higher nominal vial price may be economically competitive if it reduces discarded azacitidine, preparation labor, and failed or delayed administrations.

What is the FDA regulatory status of Vidaza?

Vidaza was approved by the FDA in 2004 for treatment of myelodysplastic syndromes. The injectable product remains a conventional small-molecule drug regulated through an NDA and generic ANDA pathway.

The FDA label describes both subcutaneous and intravenous administration. Azacitidine is not a biologic, so it does not have a biosimilar pathway. Competitors must generally demonstrate pharmaceutical equivalence and bioequivalence or satisfy the applicable product-specific requirements for an injectable generic.[1][2]

Regulatory implications for new excipient products

A generic version using the same qualitative and quantitative formulation has a comparatively direct regulatory pathway. A differentiated formulation using new excipients, new concentrations, or a liquid presentation may require:

• New drug application or 505(b)(2) development.
• Full chemistry, manufacturing, and controls development.
• Extractables and leachables evaluation.
• Container-closure integrity testing.
• Sterility and endotoxin validation.
• Comparative stability studies.
• Route-specific compatibility and administration studies.
• Potential clinical bridging if formulation changes affect exposure or tolerability.

The use of a novel excipient in an injectable oncology product increases regulatory and supply-chain risk. A strategy based on established parenteral excipients is more likely to preserve development speed.

What is the Orange Book status of Vidaza?

Vidaza's principal U.S. market exclusivity has ended. Historical U.S. patents covering azacitidine treatment methods and related uses reached expiration after the original 2004 approval period. The commercial market is therefore open to ANDA applicants, subject to current FDA listing and approval requirements.

Exclusivity issue	Vidaza assessment
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not the primary current barrier to generic entry
Composition-of-matter protection	Expired historical protection
Injectable formulation protection	No widely recognized active blocking estate comparable to a modern protected long-acting formulation
Biosimilar exclusivity	Not applicable
Generic pathway	ANDA, subject to FDA product-specific requirements
Commercial barrier	Manufacturing, supply reliability, quality, pricing, and hospital contracting

Orange Book status should be evaluated at the specific product and patent-listing level because listings, delistings, and approval status can change. Historical patent protection is not equivalent to a current market block.[2]

Which companies are challenging Vidaza exclusivity?

The relevant challengers are manufacturers pursuing FDA-approved azacitidine injection products rather than biosimilar developers. Generic competition has emerged in the U.S. after the expiry of the principal historical exclusivity and patent barriers.

The competitive field includes established injectable-drug manufacturers and generic companies with oncology portfolios. The important diligence questions are:

• Whether the applicant has final FDA approval or only tentative approval.
• Whether the product is approved for both subcutaneous and intravenous administration.
• Whether the applicant offers a 100 mg vial only or multiple strengths.
• Whether the product has a stable commercial supply record.
• Whether the company has hospital-distribution and group-purchasing access.
• Whether the product label matches Vidaza's preparation and storage conditions.

Publicly disclosed litigation is less important to current commercial entry than the existence of approved alternative products and their procurement access. Any Paragraph IV assessment should be performed against the live Orange Book patent listing and active court docket, not historical patents alone.

Does Vidaza face biosimilar risk?

No. Azacitidine is a chemically synthesized small molecule, not a biologic. Vidaza therefore faces generic substitution risk, not biosimilar risk.

This distinction affects development economics. Generic applicants may rely on pharmaceutical equivalence and bioequivalence principles, while a biosimilar applicant would need a much broader comparability package. The lower barrier supports multiple entrants and increases price pressure once procurement contracts shift from the reference product.

How strong is the Vidaza patent estate?

The Vidaza patent estate is weak as a current barrier to U.S. generic entry. Historical protection supported the original product, but the principal commercial value now lies in brand recognition, physician familiarity, treatment protocols, and distribution rather than enforceable exclusivity.

A new entrant could still build a narrower patent estate around:

• Stabilized azacitidine solutions.
• Specific pH and buffer systems.
• Low-waste vial configurations.
• Closed-system reconstitution.
• Extended in-use stability.
• Combination kits with validated administration components.
• Manufacturing processes that improve impurity control or yield.
• Solid-state or lyophilization parameters tied to performance.

Method-of-use patents are less attractive unless they identify a clinically differentiated dosing schedule, patient population, biomarker, or combination regimen. Broad claims covering azacitidine use in myelodysplastic syndromes face substantial prior-art exposure because the therapeutic use is established.

What manufacturing and intellectual-property barriers affect azacitidine products?

The active ingredient is a nucleoside analogue requiring controlled impurity management, validated sterilization strategy, and robust analytical methods. The main manufacturing risks are:

• Azacitidine degradation during aqueous processing.
• Moisture sensitivity of the lyophilized cake.
• Batch-to-batch variability in reconstitution performance.
• Particulate formation after reconstitution.
• Sterility assurance for small-volume parenteral production.
• Supply of qualified azacitidine API.
• Stability under repeated temperature excursions.
• Container-closure interaction.

A formulation patent has greater commercial value when it is linked to a difficult-to-replicate manufacturing process. Examples include a narrowly defined lyophilization cycle, controlled residual moisture profile, or impurity specification that competitors cannot easily reproduce without redesigning the process.

Trade secrets may be more durable than composition patents for process parameters, scale-up methods, and analytical controls. They do not prevent competitors from independently developing equivalent processes, but they can support supply reliability and lower cost.

How does Vidaza compare with oral azacitidine Onureg?

Vidaza and Onureg are not interchangeable products.

Attribute	Vidaza	Onureg
Active ingredient	Azacitidine	Azacitidine
Dosage form	Injectable lyophilized powder	Oral tablet
Administration	Subcutaneous or IV	Oral
Primary commercial use	Treatment cycles requiring parenteral administration	Maintenance therapy in selected AML patients
Formulation challenge	Aqueous instability, reconstitution, sterility	Oral absorption, bioavailability, release and exposure control
Substitution risk	Generic injectable competition	Separate oral-product patent and regulatory analysis
Excipient opportunity	Stability, vial size, reconstitution, waste reduction	Modified release, absorption enhancement, tablet robustness

The shared active ingredient does not make the products therapeutically or regulatorily interchangeable. An injectable Vidaza generic cannot automatically substitute for Onureg, and an Onureg patent strategy does not directly protect injectable azacitidine.

What commercial opportunities exist for Vidaza excipients and formulations?

The strongest opportunities are operational products for hospitals rather than premium products based solely on a different excipient.

Highest-value opportunities

Opportunity	Commercial attractiveness	Key risk
50 mg and 100 mg vial portfolio	High	Added manufacturing and inventory complexity
Extended in-use stability	High	Requires strong stability evidence
Ready-to-use liquid	High if technically feasible	Azacitidine aqueous instability
Dual-chamber vial or kit	Moderate to high	Device and combination-product requirements
Closed-system transfer-compatible presentation	Moderate	Hospital adoption and device validation
Lower-residual-volume container	Moderate	Limited standalone patent strength
New parenteral excipient package	Moderate	Regulatory and obviousness risk
Premixed IV bag	Moderate	Shipping, sterility, and stability burden

The most defensible product strategy combines an established excipient system with a measurable workflow advantage. A 505(b)(2) product with longer post-reconstitution stability, smaller vial sizes, and pharmacy-ready packaging could compete against both Vidaza and basic generics.

What generic launch scenarios exist for Vidaza?

Three launch scenarios are commercially realistic.

Price-led generic launch

Multiple 100 mg vial suppliers compete primarily on acquisition price. This scenario creates rapid erosion and favors manufacturers with low-cost API, efficient lyophilization, and broad distribution.

Supply-reliability launch

A manufacturer differentiates through consistent availability, dual API sourcing, short lead times, and reliable hospital contracting. This approach can preserve share even without a formulation patent.

Workflow-differentiated launch

A sponsor introduces smaller vials, longer in-use stability, or a ready-to-use system. The product may command a modest premium if it reduces pharmacy labor and drug waste.

The third scenario offers the strongest opportunity for a specialty pharmaceutical company, but it carries the greatest development and regulatory cost.

Key Takeaways

• Vidaza is a 100 mg lyophilized azacitidine injection containing mannitol as its principal excipient.
• The current U.S. market is exposed to generic competition because historical exclusivity and key patent protection have expired.
• Vidaza has no biosimilar risk because azacitidine is a small molecule.
• The strongest excipient opportunities involve stability, reconstitution, vial size, dose recovery, and pharmacy workflow.
• Mannitol itself is unlikely to support a valuable broad patent position.
• A ready-to-use liquid product could be commercially attractive but faces substantial azacitidine stability challenges.
• Smaller vials may reduce treatment-cycle waste created by body-surface-area dosing and the 100 mg presentation.
• A 505(b)(2) product with improved in-use stability or a closed-system delivery format could compete above commodity generic pricing.
• Commercial success will depend on hospital contracting, supply reliability, API economics, and validated waste reduction.
• The most practical strategy is an established-excipient formulation paired with a differentiated presentation and manufacturing process.

FAQs About Vidaza Excipient and Commercial Strategy

What is the main excipient in Vidaza injection?

Mannitol is the principal excipient in the U.S. Vidaza 100 mg lyophilized vial. Sterile water is used for reconstitution before administration.

Can a company patent a new mannitol formulation of azacitidine?

Yes, but a broad mannitol claim would face prior-art and obviousness challenges. Patentability is stronger when the formulation provides a defined stability, reconstitution, impurity, or dose-recovery advantage.

Would a 50 mg azacitidine vial have commercial value?

It could reduce unused drug for patients receiving doses below 100 mg, but the value depends on vial pricing, pharmacy batching, treatment volume, and manufacturing cost.

Is a generic azacitidine injection interchangeable with Onureg?

No. Vidaza and Onureg contain azacitidine but have different dosage forms, administration routes, exposure profiles, labels, and substitution rules.

What is the most attractive differentiated azacitidine product?

A product combining smaller vial sizes, longer validated in-use stability, low-transfer-loss packaging, and established parenteral excipients offers the most practical balance between regulatory feasibility and commercial differentiation.

References

1. U.S. Food and Drug Administration. (2024). Vidaza (azacitidine) for injection: Prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. National Library of Medicine. (2024). Vidaza-azacitidine injection, powder, lyophilized, for solution. DailyMed.

4. Bristol Myers Squibb. (2024). 2023 annual report. Bristol Myers Squibb.

5. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. FDA.